The firm is leveraging its expertise in the immuno-oncology space to expedite development of newer agents like the bispecific ...

In a Phase II trial, advanced ovarian patients with HRD alterations seemed to fare particularly well on Imunon's IMNN-001 plus standard chemo.

The platform will support Anocca's Phase I/II trial of its therapies under development for treating KRAS-mutated pancreatic cancer.

BE-101 is an engineered B-cell therapy, in which a functional copy of the FIX gene is inserted into patients' own B cells in vivo.

The partners will seek CAP/CLIA certification for an organoid-based assay and conduct clinical validation studies of it as a tool to guide treatment.

NEW YORK – ARTBio this week said it has raised $132 million in Series B financing to advance its alpha radioligand therapies and bolster the supply chain underlying their development.

Experts don't back specific tests, but provide guidelines on how doctors in specialty care settings can use them to diagnose ...

The agency previously declined to approve Atara's first Ebvallo biologics license application, but has accepted a data package it resubmitted this month.

The impact of Tagrisso plus chemo on overall survival in a Phase III trial has boosted the firms' confidence to parry competitors.

As Keytruda generic competition looms larger on the horizon, the company is hoping to reinvest the savings into pipeline ...

The firm will retain rights to its preclinical assets including two T-cell receptor T-cell therapies and its allogenic program.

Neurologists from multiple clinics shared data at AAIC on the Alzheimer's drug's use, shedding light on its safety and ...